spacer
The Healthcare Sales & Marketing Network celebrates 28 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  BTK 

 HSMN NewsFeed - 13 Apr 2026
Lilly's Jaypirca (Pirtobrutinib) Significantly Extended Progression-Free Survival When Added to a Venetoclax Time-Limited Regimen in Patients with Previously Treated CLL/SLL
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Oct 2023
MedAlliance Acquired by Cordis for up to USD 1.135 Billion
Devices Interventional Cardiology Mergers & Acquisitions
 HSMN NewsFeed - 14 Sep 2023
MedAlliance Announces Enrollment of over 1,660 Patients in Landmark SELUTION DeNovo Study
Devices Interventional Cardiology
 HSMN NewsFeed - 31 May 2023
Excellent 12-Month Results from SELUTION SFA Trial Presented at JET
Devices Interventional
 HSMN NewsFeed - 14 Mar 2023
Over 1,000 Patients Enrolled in Landmark SELUTION DeNovo Study
Devices Interventional Cardiology
 HSMN NewsFeed - 13 Feb 2023
Concept Medical granted Investigational Device Exemption (IDE) approval for their Magic Touch Sirolimus Coated Balloon for the treatment of Below the Knee (BTK) Arterial Disease
Devices Interventional FDA
 HSMN NewsFeed - 25 Jan 2023
MedAlliance leads US Sirolimus DEB race: First US Patient enrolled into SELUTION SLR Coronary Sirolimus DEB Study
Devices Interventional Cardiology
 HSMN NewsFeed - 11 Jan 2023
MedAlliance SELUTION SLR is the first DEB to receive coronary de novo IDE approval, its fourth FDA IDE DEB Approval
Devices Interventional Cardiology FDA
 HSMN NewsFeed - 25 Oct 2022
MedAlliance SELUTION SLR Receives Coronary FDA IDE Approval
Devices Interventional Cardiology FDA
 HSMN NewsFeed - 18 Oct 2022
Cordis Announces Acquisition of MedAlliance, Positioning Itself for Market Leadership in Drug-Eluting Balloon Technology
Devices Drug Delivery Mergers & Acquisitions
 HSMN NewsFeed - 18 Oct 2022
MedAlliance to be Acquired by Cordis
Devices Drug Delivery Mergers & Acquisitions
 HSMN NewsFeed - 3 Jan 2022
Curis Adds Three New Executives to Management Team Strengthening Medical Affairs, Clinical Development and Clinical Operations
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 8 Oct 2021
18-Month Below-the-Knee Data with MedAlliance's SELUTION SLR(TM) Presented as Late Breaking Trial at VIVA
Devices Interventional
 HSMN NewsFeed - 28 Sep 2021
ONO PHARMA USA Appoints David Trexler as Chief Commercial Officer to Strengthen U.S. Leadership
Biopharmaceuticals Personnel
 HSMN NewsFeed - 19 Apr 2021
Curis Receives FDA Orphan Drug Designation for CA-4948 for the Treatment of AML and MDS
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 7 Sep 2020
Ascentage Pharma's Bcl-2 Inhibitor APG-2575 Granted Orphan Drug Designation by the FDA for the Treatment of Chronic Lymphocytic Leukemia
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 27 Aug 2020
Enrolment initiated in World's First RCT with Sirolimus Coated Balloon for the treatment of Below-the-Knee (BTK) Peripheral Artery Disease
Devices Interventional
 HSMN NewsFeed - 20 Jul 2020
FDA Clears Abivertinib for Phase 2 Safety and Efficacy Study in Hospitalized Patients with Moderate To Severe Covid-19
Biopharmaceuticals FDA
 HSMN NewsFeed - 30 Jun 2020
MedAlliance Gains CE Mark Approval for Coronary SELUTION SLR(TM) Sirolimus Drug Eluting Balloon
Devices Interventional Cardiology Regulatory
 HSMN NewsFeed - 8 Nov 2019
Janssen Announces Submission of Supplemental New Drug Application to U.S. FDA Seeking Approval of IMBRUVICA(R) (ibrutinib) in Combination with Rituximab for Previously Untreated Patients with Chronic Lymphocytic Leukemia
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 2 May 2019
Concept Medical Inc. Granted 'Breakthrough Device Designation' From FDA for Its MagicTouch Sirolimus Coated Balloon
Devices Interventional Cardiology FDA
 HSMN NewsFeed - 15 Feb 2019
Lilly Completes Acquisition of Loxo Oncology
Biopharmaceuticals Oncology Mergers & Acquisitions
 HSMN NewsFeed - 28 Jan 2019
U.S. FDA Approves IMBRUVICA(R) (ibrutinib) Plus Obinutuzumab as First Non-Chemotherapy Combination Regimen for Treatment-Naïve Patients with Chronic Lymphocytic Leukemia
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 7 Jan 2019
Lilly Announces Agreement To Acquire Loxo Oncology
Biopharmaceuticals Oncology Mergers & Acquisitions
 HSMN NewsFeed - 17 Oct 2018
AbbVie Announces Supplemental New Drug Application Accepted for Priority Review by U.S. FDA for IMBRUVICA(R) (ibrutinib) in Combination with Obinutuzumab (GAZYVA(R)) for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 27 Aug 2018
AbbVie Announces IMBRUVICA(R) (ibrutinib) Plus Rituximab Approval by U.S. FDA as First Chemotherapy-Free Combination Treatment in Adults with Waldenström's Macroglobulinemia, a Rare Type of Blood Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 25 Jun 2018
IMBRUVICA(R) (ibrutinib) Supplemental New Drug Application Accepted for Review by U.S. FDA with Potential to Broaden Treatment Use as a Combination Treatment Option with Rituximab in Waldenström's Macroglobulinemia (WM), A Rare Form of Blood Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 24 May 2018
IMBRUVICA(R) (ibrutinib) Plus GAZYVA(R) (obinutuzumab) Phase 3 iLLUMINATE Trial for First-Line Therapy of Chronic Lymphocytic Leukemia (CLL) Patients Met Primary Endpoint
Biopharmaceuticals Oncology
 HSMN NewsFeed - 23 Apr 2018
Surmodics Announces FDA Clearance of a New .018” Low-Profile PTA Balloon Dilation Catheter
Devices Interventional FDA
 HSMN NewsFeed - 26 Oct 2017
Nitiloop Announces FDA 510(k) Clearance for its Nova Cross Extreme and Nova Cross BTK Micro catheter for Support of Guidewire Access to Discrete Regions of the Coronary and Peripheral Vasculature
Devices Interventional FDA
 HSMN NewsFeed - 28 Jun 2017
Adicet Bio Appoints Jesse McGreivy, M.D., Chief Medical Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 5 Jun 2017
New Data Presented at ASCO 2017 Finds IMBRUVICA(R) (ibrutinib) May Offer a More Targeted Approach to Chronic Lymphocytic Leukemia (CLL) Treatment than Chemotherapy Agent Chlorambucil in Treatment-Naïve Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 26 Apr 2017
Mercator MedSystems Announces First Enrollment in the TANGO Trial for BTK Vascular Disease
Devices Interventional Drug Delivery
 HSMN NewsFeed - 13 Feb 2017
Intact Vascular's Tack Optimized Balloon Angioplasty II Below the Knee (TOBA II BTK) Clinical Trial Commences Enrollment with First Implant of the Tack Endovascular System(R)
Devices Interventional
 HSMN NewsFeed - 19 Jan 2017
U.S. FDA Approves IMBRUVICA(R) (ibrutinib) as First Treatment Specifically Indicated for Relapsed/Refractory Marginal Zone Lymphoma (MZL) - a Rare Type of Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 26 Sep 2016
AbbVie Announces Submission of a Supplemental New Drug Application for Ibrutinib (IMBRUVICA(R)) for Treatment of Marginal Zone Lymphoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 25 Aug 2016
Sunesis Announces Publication in "Drugs" Detailing Molecular and Pharmacologic Properties of Vosaroxin
Biopharmaceuticals Oncology
 HSMN NewsFeed - 29 Jun 2016
AbbVie Announces Fourth Breakthrough Therapy Designation Granted by the U.S. Food and Drug Administration (FDA) for Ibrutinib (IMBRUVICA(R)) for Chronic Graft-Versus-Host-Disease (cGVHD), a Rare Condition with Limited Treatment Options
Biopharmaceuticals
 HSMN NewsFeed - 9 May 2016
U.S. FDA Expands IMBRUVICA(R) (ibrutinib) Label to Include Overall Survival Data in Previously Untreated Chronic Lymphocytic Leukemia (CLL) and New Indication for Small Lymphocytic Lymphoma (SLL) Patients
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 8 Feb 2016
STENTYS initiates the Commercialization of the first Self-Expanding Drug-Eluting stent for the Below-The-Knee Indication
Devices Interventional Product Launch
 HSMN NewsFeed - 13 Nov 2015
AbbVie Submits IMBRUVICA(R) (ibrutinib) Phase III Combination Data to U.S. FDA
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 15 Sep 2015
Molecular Response Appoints the Former Head of Translational Medicine Oncology at MedImmune/AstraZeneca, Brett Hall, Ph.D., as Chief Executive Officer
Diagnostics Personnel
 HSMN NewsFeed - 19 Nov 2014
Cordis Corporation Leads With Strong Podium Presence At VEITH 2014 With First-Ever Presentation Of Three-Year INCRAFT(R) System Data
Devices Interventional
 HSMN NewsFeed - 4 Sep 2014
EndoCross Receives CE Mark Approval for the ENABLER-C Coronary Catheter System for the Crossing of Coronary Chronic Total Occlusions
Devices INterventional Cardiology Regulatory
 HSMN NewsFeed - 25 Jul 2014
European Medicines Agency (EMA) Issues Positive Opinion, Recommends Full Approval of IMBRUVICA(R) (ibrutinib) for Treatment of Two Blood Cancers
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 13 Feb 2014
Medtronic Launches 'TOTAL Across' Crossing Catheter in Europe
Devices Interventional Product Launch
 HSMN NewsFeed - 13 Feb 2014
Principia Biopharma Expands Executive Management Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Apr 2013
Ibrutinib Receives Third Oncology Breakthrough Therapy Designation from U.S. Food and Drug Administration
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 25 Jan 2013
AngioScore Launches New 100 mm Length AngioSculpt(R) Scoring Balloons For Treatment of Peripheral Artery Disease Below The Knee (BTK)
Devices Interventional Product Launch
 HSMN NewsFeed - 2 May 2012
Angioslide Announces FDA 510(K) Clearance of PROTEUS(TM) Below The Knee Device
Devices Interventional FDA
 HSMN NewsFeed - 7 Mar 2012
Abbott's Absolute Pro(R) Vascular Self-Expanding Stent System Receives FDA Approval for Treatment of Iliac Artery Disease
Devices Interventional FDA
 HSMN NewsFeed - 26 Jan 2012
Celgene to Acquire Avila Therapeutics
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 22 Dec 2011
Abbott Initiates Clinical Trial to Study Drug Eluting Bioresorbable Therapy for Treatment of Peripheral Artery Disease
Devices Interventional
 HSMN NewsFeed - 18 Oct 2011
BIOTRONIK Launches First 20 mm–200 mm Stents on 4 F Platform for Treatment of SFA and BTK Disease
Devices Interventional
 HSMN NewsFeed - 8 Sep 2011
Abbott Initiates International ABSORB BTK Clinical Trial for Treatment of Below-the-Knee Critical Limb Ischemia
Devices
 HSMN NewsFeed - 13 Jun 2011
Pathway Medical Technologies Expands JETSTREAM G3 SF Family With FDA 510(k) Clearance for 1.6 mm Catheter
Devices Interventional FDA
 HSMN NewsFeed - 1 Apr 2011
AngioScore Launches New Longer AngioSculpt(R) Devices for Treatment of Peripheral Artery Disease
Devices Interventional FDA
 HSMN NewsFeed - 10 Nov 2010
BIOTRONIK AG, Vascular Intervention - Introducing Pulsar-18: The world’s first 4 F-compatible self-expanding stent with lengths up to 200 mm
Devices Interventional
 HSMN NewsFeed - 28 Sep 2010
Medtronic Advances Research on Drug-Eluting Balloons for Coronary and Peripheral Artery Disease
Devices Interventional Cardiology
 HSMN NewsFeed - 21 Jun 2010
Boston Scientific Expands PolarCath(R) Peripheral Dilatation System With New Balloon Sizes
Devices Interventional
 HSMN NewsFeed - 21 Jun 2010
Pathway Medical Technologies Receives FDA 510(k) Clearance for JETSTREAM G3 SF Atherectomy System
Devices Interventional FDA
 HSMN NewsFeed - 29 Jan 2010
Invatec Comments on First Clinical Results of Drug Eluting Balloon Technology for Below the Knee (BtK)
Devices Interventional
 HSMN NewsFeed - 27 Jul 2009
Avila Therapeutics, Inc. Closes $30 Million Series B Financing
Biopharmaceuticals Venture Capital Personnel
 HSMN NewsFeed - 31 Mar 2009
Invatec Introduces AMPHIRION DEEP Long Balloon to More Easily Access and Treat Arteries Below the Knee
Devices Interventional FDA
 HSMN NewsFeed - 21 Dec 2007
Pharmacyclics Receives Non-Approvable Letter from the FDA for Xcytrin for the Treatment of Lung Cancer Brain Metastases
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 26 Mar 2007
CryoPlasty(R) Provides Alternative to Amputation For Patients With Blocked Arteries Below The Knee
Devices Interventional
 HSMN NewsFeed - 20 Mar 2007
Boston Scientific Announces Schedule for ACC 2007
Devices Interventional Cardiology
 HSMN NewsFeed - 29 Jan 2007
FDA Grants Boston Scientific Clearance to Expand PolarCath(TM) Peripheral Dilatation System Offering with New Balloon Length
Devices Interventional FDA
 HSMN NewsFeed - 26 Sep 2006
Boston Scientific Announces Excellent Results for Patients With Blocked Arteries Below the Knee
Devices Interventional
Return to NewsFeed  
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.